021 439 8008
021 439 8008
More than half of health conscious people suffer from digestive health problems
Professor Leon Dicks
More than half (54%) of health-conscious South Africans experience digestive health problems, according to the 2017 Cipla Digestive Health Survey conducted among 400 health conscious individuals. Respondents indicated that 77% suffer from bloating, 76% said they have constipation and 28% experience regular diarrhoea.
Please see the full media release and a link to a short video below for further information.
Professor Leon Dicks is available for interviews during office hours to discuss the following:
- Why so many people experience digestive health problems
- The benefits of taking a probiotic on a daily basis
- How to choose the right probiotic
Please contact me if you are interested in an interview with Prof. Dicks and I will gladly arrange it for you.
MORE THAN HALF OF HEALTH CONSCIOUS PEOPLE SUFFER FROM DIGESTIVE HEALTH PROBLEMS
14 September 2017: More than half (54%) of health-conscious South Africans experience digestive health problems, according to the 2017 Cipla Digestive Health Survey conducted among 400 health conscious individuals. Respondents indicated that 77% suffer from bloating, 76% said they have constipation and 28% experience regular diarrhoea.
Professor Leon Dicks, head of the probiotic and antimicrobial peptide lab in the Department of Microbiology at the Stellenbosch University, says that digestive health problems are caused by an imbalance of bacteria (microflora) in your gut. “Factors which can cause an imbalance of microflora in your gut include stress, lack of exercise, smoking, improper diet, travelling and anti-biotics to name a few.”
Among the group of respondents of Cipla’s Digestive Health Survey, only 22% were daily users of probiotics, while 35% of respondents of the survey indicated that they take a probiotic once a week.
Professor Dicks recommends that all people take a quality probiotic daily to maintain a balance of microflora in the gut. He explains that a probiotic consists of live bacteria which disappear, together with their health benefits after a day. “Taking a daily probiotic will not only reduce your chances of experiencing digestive health problems, but will also promote a well-balanced immune system since about 75% of the body’s immune system is located in the gut.”
The survey found that 66% of the respondents believe that by consuming yoghurt daily they can achieve their daily requirement of probiotics. However, Professor Dicks notes that the yoghurt cultures contained in one serving are not nearly enough. “In fact a person needs to consume about 40 litres of yoghurt per day to take in the required amount of probiotic flora needed to maintain a healthy gut.”
He adds that when choosing a probiotic, consumers must select a probiotic which line both the small and large intestine, which will be indicated on the packet. "It is therefore not about the number of strains in the probiotic but whether the strains lines, binds and protect the entire gut.”
“There is no reason why so many people should experience digestive health problems. A good probiotic taken daily will help maintain digestive health and boost the immune system which will help people achieve an overall healthier, quality of life,” concludes Professor Dicks.
About Cipla Medpro:
Cipla Medpro - the fourth largest pharmaceutical manufacturer in South Africa - is a leading provider of affordable medicines to the public and private sectors. Cipla Medpro manufactures world class pharmaceuticals at cost-effective prices, making quality medicines affordable, and advancing healthcare for all South Africans.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. For more than 82 years, Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 80 countries. Cipla’s portfolio includes more than 1 500 products in 65 therapeutic categories with one quality standard globally. Cipla has over 35 internationally approved facilities and employs more than 24 700 people. Cipla’s turnover in FY 2013-14 was 1.7 billion USD.
Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla’s emphasis on access for patients was recognized globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than one dollar a day and thereby treating many millions of patients since 2001.
Cipla’s research and development focuses on developing innovative products and drug delivery systems and has given India and the world many ‘firsts’ for instance Triomune. In a tightly regulated environment, the company’s manufacturing facilities have approvals from all the main regulators including US FDA, UKMHRA, WHO, MCC, ANVISA, and PMDA which means the company provides one universal standard both domestically and internationally.